Evaluation of posaconazole plasma concentrations achieved with the delayed-release tablets in Korean high-risk patients with haematologic malignancy

Autor: Hee-Je Kim, Dong-Gun Lee, Yunmi Yi, Hyojin Chae, Yonggoo Kim, Yoo-Jin Kim, Jeong Joong Lee, Myungshin Kim, Sung-Yeon Cho, Kyoungho Cha
Rok vydání: 2019
Předmět:
0301 basic medicine
Adult
Male
Posaconazole
medicine.medical_specialty
Heterozygote
Antifungal Agents
medicine.drug_class
030106 microbiology
Proton-pump inhibitor
Biological Availability
Dermatology
Neutropenia
Gastroenterology
Cohort Studies
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
Tandem Mass Spectrometry
Haematologic malignancy
Internal medicine
Medicine
Humans
Glucuronosyltransferase
Retrospective Studies
Polymorphism
Genetic
medicine.diagnostic_test
business.industry
General Medicine
Middle Aged
Triazoles
medicine.disease
Bioavailability
Infectious Diseases
Graft-versus-host disease
Liver
Therapeutic drug monitoring
Pharmacogenetics
Delayed-Action Preparations
Hematologic Neoplasms
Plasma concentration
Multivariate Analysis
Regression Analysis
Female
business
medicine.drug
Chromatography
Liquid
Tablets
Zdroj: MycosesREFERENCES. 63(2)
ISSN: 1439-0507
Popis: BACKGROUND Posaconazole (PCZ) is a triazole approved for prophylaxis of invasive fungal infections. OBJECTIVES Herein, the impact of clinical variables on PCZ plasma concentrations (PPCs) attained with PCZ delayed-release tablet (DRT) was investigated and compared with a historical cohort treated with PCZ oral suspension (OS). PATIENTS/METHODS Steady-state PCZ PPCs in 513 patients with haematologic malignancy treated with PCZ-DRT were assessed and impact of variables were analysed. Also, a comparison with matched historical cohort treated with PCZ-OS was made. RESULTS The median PPC in the PCZ-DRT group was 1,308.9 ng/mL (range: 29.8-10 455.9). Use of proton pump inhibitor (1181 vs 1344 ng/mL, P = .0337) in the AML/myelodysplastic syndrome remission induction group, diarrhoea (867 vs 1543 ng/mL, P = .0325) and gastrointestinal graft-versus-host disease (870 vs 1713 ng/mL, P = .0178) in the HSCT group were associated with lower PPCs. There was lack of evidence that hepatotoxicity was related with PCZ-DRT. Higher prevalence of UGT1A4*3 allele (33.0%) was noted compared to allele frequency in Koreans in those with PPCs
Databáze: OpenAIRE
Externí odkaz: